Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$39.72
0.471.20%
At close: -
$39.72
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Apogee Therapeutics Analyst Ratings and Price Targets | NASDAQ:APGE | Benzinga
Apogee Therapeutics Inc has a consensus price target of $81 based on the ratings of 9 analysts. The high is $95 issued by Citigroup on March 13, 2025. The low is $43 issued by BTIG on December 20, 2023. The 3 most-recent analyst ratings were released by Citigroup, Guggenheim, and Wedbush on March 13, 2025, December 3, 2024, and December 2, 2024, respectively. With an average price target of $98.33 between Citigroup, Guggenheim, and Wedbush, there's an implied 147.57% upside for Apogee Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Wedbush
Canaccord Genuity
B of A Securities
Jefferies
1calculated from analyst ratings
Analyst Ratings for Apogee Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/13/2025 | Buy Now | 139.17% | Citigroup | Geoff Meacham63% | → $95 | Initiates | → Buy | Get Alert |
| 02/10/2025 | Buy Now | — | Guggenheim | Seamus Fernandez61% | — | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | — | Guggenheim | Seamus Fernandez61% | — | Reiterates | Buy → Buy | Get Alert |
| 12/03/2024 | Buy Now | 176.94% | Guggenheim | Seamus Fernandez61% | $95 → $110 | Reiterates | Buy → Buy | Get Alert |
| 12/02/2024 | Buy Now | 126.59% | Wedbush | David Nierengarten62% | $87 → $90 | Maintains | Outperform | Get Alert |
| 11/27/2024 | Buy Now | 176.94% | Guggenheim | Seamus Fernandez61% | $95 → $110 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 124.07% | Canaccord Genuity | Edward Nash66% | → $89 | Initiates | → Buy | Get Alert |
| 10/25/2024 | Buy Now | 119.03% | Wedbush | David Nierengarten62% | $87 → $87 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2024 | Buy Now | 101.41% | B of A Securities | Geoff Meacham63% | → $80 | Initiates | → Buy | Get Alert |
| 03/06/2024 | Buy Now | 88.82% | Jefferies | Akash Tewari44% | $37 → $75 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 139.17% | Stifel | Akash Tewari44% | $46 → $95 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 129.1% | Guggenheim | Seamus Fernandez61% | $44 → $91 | Maintains | Buy | Get Alert |
| 01/03/2024 | Buy Now | 10.78% | Guggenheim | Seamus Fernandez61% | $29 → $44 | Maintains | Buy | Get Alert |
| 12/20/2023 | Buy Now | 8.26% | BTIG | Julian Harrison41% | → $43 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | — | TD Cowen | Tyler Van Buren48% | — | Initiates | → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 0.7% | Wedbush | David Nierengarten62% | → $40 | Initiates | → Outperform | Get Alert |
| 08/08/2023 | Buy Now | -14.4% | Stifel | Akash Tewari44% | → $34 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | -26.99% | Jefferies | Akash Tewari44% | → $29 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | -26.99% | Guggenheim | Seamus Fernandez61% | → $29 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Apogee Therapeutics (APGE) stock?
The latest price target for Apogee Therapeutics (NASDAQ:APGE) was reported by Citigroup on March 13, 2025. The analyst firm set a price target for $95.00 expecting APGE to rise to within 12 months (a possible 139.17% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Apogee Therapeutics (APGE)?
The latest analyst rating for Apogee Therapeutics (NASDAQ:APGE) was provided by Citigroup, and Apogee Therapeutics initiated their buy rating.
When was the last upgrade for Apogee Therapeutics (APGE)?
There is no last upgrade for Apogee Therapeutics
When was the last downgrade for Apogee Therapeutics (APGE)?
There is no last downgrade for Apogee Therapeutics.
When is the next analyst rating going to be posted or updated for Apogee Therapeutics (APGE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apogee Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apogee Therapeutics was filed on March 13, 2025 so you should expect the next rating to be made available sometime around March 13, 2026.
Is the Analyst Rating Apogee Therapeutics (APGE) correct?
While ratings are subjective and will change, the latest Apogee Therapeutics (APGE) rating was a initiated with a price target of $0.00 to $95.00. The current price Apogee Therapeutics (APGE) is trading at is $39.72, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.